Bimekizumab
- Generic Name
- Bimekizumab
- Brand Names
- Bimzelx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418205-77-2
- Unique Ingredient Identifier
- 09495UIM6V
- Background
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 ...
- Indication
Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 274
- Registration Number
- NCT03928704
- Locations
- ๐ง๐ช
As0010 40004, Bruxelles, Belgium
๐บ๐ธAs0010 50060, Upland, California, United States
๐บ๐ธAs0010 50016, Saint Louis, Missouri, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 332
- Registration Number
- NCT03928743
- Locations
- ๐ซ๐ท
As0011 40018, Boulogne Billancourt, France
๐ฏ๐ตAs0011 20032, Suita, Japan
๐ต๐ฑAs0011 40039, Wroclaw, Poland
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 400
- Registration Number
- NCT03896581
- Locations
- ๐บ๐ธ
Pa0011 50004, Tustin, California, United States
๐บ๐ธPa0011 50035, San Diego, California, United States
๐บ๐ธPa0011 50017, Phoenix, Arizona, United States
A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 56
- Registration Number
- NCT03895385
- Locations
- ๐บ๐ธ
Up0034 001, San Antonio, Texas, United States
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 852
- Registration Number
- NCT03895203
- Locations
- ๐ฉ๐ช
Pa0010 40026, Ratingen, Germany
๐ญ๐บPa0010 40030, Eger, Hungary
๐ฎ๐นPa0010 40084, Catania, Italy
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 172
- Registration Number
- NCT03766685
- Locations
- ๐บ๐ธ
Dv0002 962, Owensboro, Kentucky, United States
๐จ๐ฆDv0002 651, Richmond Hill, Canada
๐จ๐ฆDv0002 670, Windsor, Canada
A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 189
- Registration Number
- NCT03707717
- Locations
- ๐บ๐ธ
Up0033 002, Baltimore, Maryland, United States
๐ฉ๐ชUp0033 001, Berlin, Germany
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 1353
- Registration Number
- NCT03598790
- Locations
- ๐บ๐ธ
Ps0014 956, Verona, New Jersey, United States
๐บ๐ธPs0014 951, Webster, Texas, United States
๐จ๐ฆPs0014 659, Calgary, Canada
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 743
- Registration Number
- NCT03536884
- Locations
- ๐ฉ๐ช
Ps0015 222, Tuebingen, Germany
๐ต๐ฑPs0015 355, Bialystok, Poland
๐น๐ทPs0015 763, Gaziantep, Turkey
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 478
- Registration Number
- NCT03412747
- Locations
- ๐บ๐ธ
Ps0008 905, Overland Park, Kansas, United States
๐จ๐ณPs0008 755, Taipei, Taiwan
๐ญ๐บPs0008 260, Szeged, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.